| Market Cap | 4.17M | P/E | - | EPS this Y | 11.40% | Ern Qtrly Grth | - |
| Income | -8.95M | Forward P/E | -0.21 | EPS next Y | -4.70% | 50D Avg Chg | -52.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -82.00% |
| Dividend | N/A | Price/Book | 0.27 | EPS next 5Y | - | 52W High Chg | -98.00% |
| Recommedations | 2.00 | Quick Ratio | 3.64 | Shares Outstanding | 879.18K | 52W Low Chg | 8.00% |
| Insider Own | 8.15% | ROA | -96.34% | Shares Float | 480.93K | Beta | 0.58 |
| Inst Own | 1.26% | ROE | -202.15% | Shares Shorted/Prior | 12.99K/31.09K | Price | 1.33 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 198,160 | Target Price | 19.50 |
| Oper. Margin | - | Earnings Date | May 8 | Volume | 247,848 | Change | 3.91% |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Walsh Deina H | Chief Financial Offi.. Chief Financial Officer | Sep 13 | Buy | 0.64 | 8,000 | 5,120 | 15,000 | 09/14/23 |
| Walsh Deina H | Chief Financial Offi.. Chief Financial Officer | Sep 06 | Buy | 0.71 | 7,000 | 4,970 | 7,000 | 09/07/23 |
| Frelick Jeff | Chief Executive Offi.. Chief Executive Officer | Aug 31 | Buy | 0.6605 | 7,600 | 5,020 | 7,704 | 09/05/23 |